Here's Why You May Not Want a Medicare Advantage Plan in 2026

Medicare Advantage plans, sold by private insurers and required to at least match original Medicare, often provide supplemental benefits and annual out-of-pocket limits that appeal to retirees on fixed incomes. However, material drawbacks highlighted include restrictive provider networks that can exclude long-time doctors, frequent prior-authorization requirements and denials that delay care, and limited portability for beneficiaries who split time between states—factors likely to influence enrollee plan choice, network utilization, and potential regulatory scrutiny of plan practices.

Analysis

Market structure: Medicare Advantage growth is a continued net positive for large, vertically integrated insurers (UnitedHealth UNH, Humana HUM, Elevance ELV, CVS/CVS Health) who enjoy capitation, risk-adjustment tailwinds and tighter provider networks that can generate ~100–300 bps incremental underwriting margin versus fee‑for‑service peers. Smaller hospitals and independent specialists (HCA, UHS, regional systems) are the losers because narrow networks and prior‑auth push volume and bargaining power to payors, pressuring outpatient pricing and elective procedure revenue over 6–18 months.

Risk assessment: The main tail risks are regulatory (CMS MA payment formula resets, RADV audit clawbacks) and political (mid‑term/2026 Medicare scrutiny) that could compress near‑term EPS by 5–15% for incumbents if enacted within 3–12 months. Hidden dependencies include utilization declines from prior‑auth that lower short‑term claims but increase long‑term morbidity/liability and litigation risk; watch CMS notices and RADV outcomes for magnitude signals (threshold: >3% payment change or >$1B aggregate clawback triggers reassessment).

Trade implications: Tactical bias is long large-cap MA insurers and short fragmented acute care providers. Implement size‑constrained longs (1–2% portfolio) in UNH/ELV and pair shorts in HCA/UHS to capture a 6–12 month structural spread as MA enrollment increases through annual open enrollment (Oct–Dec) and CMS guidance cycles. Use defined‑risk option structures (6–12 month call spreads) to express upside while capping volatility from regulatory headlines.

Contrarian angles: Consensus underestimates that consumer dissatisfaction (doctor access, dual‑state snowbirds) could slow marginal MA net enrollment growth by 2–4 percentage points in pockets, creating localized provider pricing power swings; however demographic tailwinds make a full reversal unlikely. Historical parallels to Medicaid managed‑care expansion show short regulatory shocks create buying opportunities in large insurers; unintended consequence: sustained prior‑auth could provoke legislative caps that temporarily transfer margin back to providers.

Key Decisions for Investors

• Establish a 1.5% long position in UnitedHealth (UNH) sized to 1.5% of portfolio weight over 1–12 months; target +15–20% upside and set a hard stop at -8% or on any CMS proposal that reduces MA payments >3% YoY.
• Initiate a pair trade: go 1% long Humana (HUM) and 1% short HCA Healthcare (HCA) with a 3–9 month horizon to capture MA insurer vs hospital spread; trim the short if HUM underperforms UNH by >5% in 30 days or if HCA reports inpatient volumes up +5% QoQ.
• Buy defined‑risk option exposure: purchase 6–12 month call spreads on Elevance Health (ELV) equal to 0.5–1.0% notional (buy ATM call, sell higher strike ~10–15% OTM) to participate in upside while limiting premium loss if regulatory volatility spikes; close if implied volatility >40% or CMS announces RADV clawbacks >$500M for a single issuer.
• Reduce direct exposure to small/medium hospital equities (e.g., cut HCA/UHS weight by ~20% over next 30 days) and reallocate proceeds into investment‑grade insurer bonds (BBB/ A‑ rated) or insurer equities (UNH/ELV) to lock yield and lower idiosyncratic regulatory risk; revisit after CMS open enrollment and payment rule finalization (~60 days).